June 18, 2024 02:57 PM EDT
Pharma
Cell/Gene Tx
FDA+

FDA loosens side ef­fect re­port­ing re­quire­ments for some CAR-T ther­a­pies

Nicole DeFeudis

Editor

The FDA is no longer re­quir­ing the re­port­ing of two com­mon — and some­times se­ri­ous — side ef­fects for a hand­ful of CAR-T ther­a­pies in an ef­fort …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times